/
IVF
$2.02-$0.46 (-18.78%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.4M
2M shares
52-week range
$1.20 – $169.60
0% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
365.26%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-210.41
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $494.4K | $1.5M | $1.0M | $4.2M | $822.2K | $3.0M | $6.5M | $6.8M |
| Cost of revenue | $90.4K | $139.7K | $88.8K | $145.1K | $850.8K | $1.9M | $3.7M | $4.3M |
| Gross profit | $404.0K | $1.3M | $948.5K | $4.0M | −$28.6K | $1.1M | $2.9M | $2.5M |
| Gross margin | 81.7% | 90.6% | 91.4% | 96.5% | -3.5% | 36.0% | 44.0% | 37.0% |
| R&D | $0 | $0 | $398.4K | $216.4K | $544.0K | $165.9K | $489.7K | $0 |
| Operating income | −$2.6M | −$1.8M | −$5.5M | −$5.2M | −$10.6M | −$6.8M | −$8.1M | −$5.8M |
| EBITDA | −$2.6M | −$1.8M | −$5.5M | −$5.2M | −$10.8M | −$6.9M | −$7.1M | −$3.5M |
| Net income | −$3.1M | −$2.2M | −$8.3M | −$6.7M | −$10.9M | −$8.0M | −$9.1M | −$23.3M |
| Net margin | -622.2% | -146.4% | -804.7% | -160.0% | -1324.8% | -266.0% | -139.3% | -340.9% |
| EPS (diluted) | -3.87 | -2.69 | -9.21 | -1099.64 | -1570.91 | -489.96 | -219.56 | -66.11 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10M | $-2.90 | $-2.90–$-2.90 | 1 |
| 2027 | $16M | $-1.00 | $-1.00–$-1.00 | 1 |
| 2028 | $26M | $0.35 | $0.35–$0.35 | 1 |
| 2029 | $39M | $1.25 | $1.25–$1.25 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
INVO Fertility, Inc. Common Stock
INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The company's segments include: The Clinics Services operating segment consisting of financial information for WFI and the Atlanta Clinic and The INVOcell Device operating segment consisting of financial information relating to the manufacture and sales of the INVOcell.
www.invobioscience.com- Employees
- 46
- IPO / List date
- Nov 11, 2008
- HQ
- SARASOTA, FL
Held by traders on TradeandTell
No one on the platform currently holds IVF.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in IVF as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-03-27 | 1-for-5reverse |
| 2025-11-28 | 1-for-8reverse |
| 2025-07-21 | 1-for-3reverse |
Recent trades on TradeandTell
No one on the platform has traded IVF yet.
